N.H.--(BUSINESS WIRE)--Jan. 24, 2005--Advances in nanotechnology
that enable drugs to be delivered in ways that preserve their
efficacy and to precise therapeutic targets are creating a
host of opportunities for drug developers. A variety of nanostructures
are being investigated as functional drug carriers for a wide
range of therapies, most notably cardiovascular medicine,
autoimmune diseases, and cancer.
"While the concept of nanoparticles in drug delivery
is not new, the number of research programs and active drug
development projects has escalated as funding to nanotechnology
developers has increased," explains George Perros, Greystone
Managing Director. "The result is the emergence of a
host of novel nanotechnologies tailored to meet the physicochemical
requirements of drug developers."
Nanoparticles have already
improved the availability and efficacy of some drugs, but
the capabilities that evolving technologies possess will leads
to a dramatic increase in the number of therapies delivered
via nanoparticles. In many cases drugs in nanocrystalline
form can be administered in smaller doses because they can
be delivered directly to the tissue and in controlled doses
related to the patient's personal requirements.
These findings are contained
in a new and comprehensive report: Nanoparticle Drug Delivery:
Technology, Therapies, and Prospects. The survey concludes
that nanoparticle-based drug delivery will gain traction at
the expense of traditional drug formulation methods, particularly
among emerging biologics.
More information is available
Greystone Associates is a
medical and healthcare technology consulting firm providing
services in strategic planning, venture development, product
commercialization, and technology and market assessment.
Mark Smith, 603-595-4340